Mukka Proteins Limited — Important, 04-02-2025: General Updates

In-principal approvals have been granted by both the National Stock Exchange of India and BSE for the issuance of 1,96,00,000 equity shares at a price of not less than ₹50 each. This preferential issue will cater to both promoter and non-promoter categories. The company is moving forward with the necessary compliance to execute this capital raise, which could enhance its financial flexibility and support growth initiatives. Stakeholders should be aware that this process demands strict adherence to guidelines and internal controls to ensure no regulatory non-compliance arises, particularly in trading activities related to the newly issued shares. Overall, this development presents a positive outlook for Mukka Proteins Limited's capital structure and growth potential.